PDCD1 and cancer: Checkpoint inhibitors have taken center stage in cancer immunotherapy research, since they block signaling through immune inhibitory molecules, especially programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4) (53, 54).